← Leaderboards
David Wald
Louis Stokes Cleveland Va Medical Center
$7,869,304
Attributed
$9,817,184
Total exposure
17
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2012–25$2.5M$1.9M$1.3M$625K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,817,184 · 15
VA$0 · 2
By mechanism
R01$4,099,174 · 3
R44$2,618,586 · 2
R43$959,017 · 3
R21$788,015 · 2
P30$721,763 · 4
P50$630,629 · 1
Top collaborators
- Mukesh Kumar Agarwal2 shared
- Yongchun Hou2 shared
- Mark W Jackson2 shared
- Agata A Exner1 shared
- Kelsey H Fisher-Wellman1 shared
- Nethrie Idippily-Singh1 shared
- David Soler1 shared
- Boaz Tirosh1 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsIn VivoNormal CellLeadMalignant NeoplasmsClinical TrialsPropertyExhibitsIn VitroMouse ModelCessation Of LifeToxic EffectNeoplastic CellSolid NeoplasmCancer CellAcute Myelocytic LeukemiaTumorBaseCancer TherapyImmunodeficient MouseHematopoieticAnimalsCancer PatientBiological
Grant awards (38)
Ultra-fast manufactured CAR-T therapy$1,125,000
R44 · FY2025 · CA · contact PI
Creating a transient metabolic catastrophe for AML therapy$491,357
R01 · FY2025 · CA
HTS for the discovery of activators of NK cell cytotoxicity$355,075
R01 · FY2025 · CA · contact PI
Hematopoietic Biorepository and Cellular Therapy$124,218
P30 · FY2025 · CA · contact PI
Targeting metabolism in AML$0
I01 · FY2025 · VA · contact PI
Development of a novel pan-cancer CAR-T product against AML and Glioblastoma$400,000
R43 · FY2024 · CA
Hematopoietic Biorepository and Cellular Therapy Shared Resource$107,656
P30 · FY2024 · CA · contact PI
HTS for the discovery of activators of NK cell cytotoxicity$1
R01 · FY2024 · CA · contact PI
Targeting metabolism in AML$0
I01 · FY2024 · VA · contact PI
HTS for the discovery of activators of NK cell cytotoxicity$372,835
R01 · FY2023 · CA · contact PI
Hematopoietic Biorepository and Cellular Therapy Shared Resource$107,656
P30 · FY2023 · CA · contact PI
Targeting metabolism in AML$0
I01 · FY2023 · VA · contact PI
HTS for the discovery of activators of NK cell cytotoxicity$430,887
R01 · FY2022 · CA · contact PI
Targeting metabolism in AML$0
I01 · FY2022 · VA · contact PI
HTS for the discovery of activators of NK cell cytotoxicity$454,818
R01 · FY2021 · CA · contact PI
Development of a novel imaging modality for adoptive cell therapy$413,974
R21 · FY2021 · CA · contact PI
NK Cell Therapy of Human Colorectal Cancer.$232,499
P50 · FY2021 · CA · contact PI
Targeting metabolism in AML$0
I01 · FY2021 · VA · contact PI
ShEEP Request for an X-Ray Irradiation System$0
IS1 · FY2021 · VA · contact PI
NK Cell Therapy of Human Colorectal Cancer.$190,745
P50 · FY2020 · CA · contact PI
Hematopoietic Biorepository and Cellular Therapy Shared Resource$125,786
P30 · FY2020 · CA · contact PI
Targeting GSK3 in AML$268,737
R43 · FY2019 · CA
NK Cell Therapy of Human Colorectal Cancer.$207,385
P50 · FY2019 · CA · contact PI
Hematopoietic Biorepository and Cellular Therapy Shared Resource$121,991
P30 · FY2019 · CA · contact PI
AML differentiation therapy$67,200
R43 · FY2019 · CA
AML differentiation therapy$223,080
R43 · FY2018 · CA
Hematopoietic Biorepository and Cellular Therapy Shared Resource$125,198
P30 · FY2018 · CA · contact PI
Hematopoietic Biorepository and Cellular Therapy Shared Resource$9,258
P30 · FY2018 · CA · contact PI
Original Phase 1 Title: Identifying Small Molecule Inhibitors of HdmX using Cell-based Screening Revised Title: Development of a Novel HdmX Inhibitor for Leukemia$717,790
R44 · FY2016 · CA
Mechanisms of preferential targeting of colon cancer by a plant-derived alkaloid$392,500
R01 · FY2016 · AT · contact PI
Original Phase 1 Title: Identifying Small Molecule Inhibitors of HdmX using Cell-based Screening Revised Title: Development of a Novel HdmX Inhibitor for Leukemia$775,796
R44 · FY2015 · CA
Mechanisms of preferential targeting of colon cancer by a plant-derived alkaloid$380,725
R01 · FY2015 · AT · contact PI
Mechanisms of preferential targeting of colon cancer by a plant-derived alkaloid$67,026
R01 · FY2015 · AT · contact PI
Mechanisms of preferential targeting of colon cancer by a plant-derived alkaloid$380,725
R01 · FY2014 · AT · contact PI
A Strategy for Reactivating p53 in Cancer Stem Cells Using a Novel HdmX Inhibitor$167,198
R21 · FY2014 · CA
Mechanisms of preferential targeting of colon cancer by a plant-derived alkaloid$380,725
R01 · FY2013 · AT · contact PI
A Strategy for Reactivating p53 in Cancer Stem Cells Using a Novel HdmX Inhibitor$206,843
R21 · FY2013 · CA
Mechanisms of preferential targeting of colon cancer by a plant-derived alkaloid$392,500
R01 · FY2012 · AT · contact PI